{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:55:51Z","timestamp":1769684151448,"version":"3.49.0"},"reference-count":70,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Catastrophic antiphospholipid syndrome (CAPS) is a rare, potentially lethal, multiple-faceted, systemic disease, often triggered by a precipitating factor. Its tissue lesions are mainly the consequence of an antiphospholipid antibody (aPL Abs)-mediated thrombotic microangiopathy associated with a so-called cytokine storm. Bleeding may coexist, making it difficult to manage. In an emergency situation, the differential diagnosis is not always straightforward in patients not known to be aPL Abs carriers, or with no history of thrombotic or obstetric complications. What we have gradually learned about its clinical presentation and therapeutic management mainly comes from the CAPS registry. So far, there have been no randomized controlled trials to guide treatment. The current therapeutic recommendations insist on prescribing first-line triple therapy, combining early anticoagulation, immunosuppression, and the removal\/neutralization of aPL Abs, as early as possible. The prognosis has improved but remains bleak. Future research to develop pathophysiological treatments blocking the activation of target cells by aPL Abs is warranted.<\/jats:p>","DOI":"10.1055\/a-2765-9663","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:08:51Z","timestamp":1769645331000},"source":"Crossref","is-referenced-by-count":0,"title":["Catastrophic Antiphospholipid Syndrome"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-9910","authenticated-orcid":false,"given":"Jean-Christophe","family":"Gris","sequence":"additional","affiliation":[{"name":"Department of Haematology, CHU N\u00eemes, Univ Montpellier, N\u00eemes, France"},{"name":"UMR 1318 INSERM-INRIA-Universit\u00e9 de Montpellier IDESP, Montpellier University, Montpellier, France"},{"name":"Department of Obstetrics, Gynaecology and Perinatal Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-8163","authenticated-orcid":false,"given":"Mathias","family":"Chea","sequence":"additional","affiliation":[{"name":"Department of Haematology, CHU N\u00eemes, Univ Montpellier, N\u00eemes, France"},{"name":"UMR 1318 INSERM-INRIA-Universit\u00e9 de Montpellier IDESP, Montpellier University, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-7783","authenticated-orcid":false,"given":"Antonia","family":"Perez-Martin","sequence":"additional","affiliation":[{"name":"UMR 1318 INSERM-INRIA-Universit\u00e9 de Montpellier IDESP, Montpellier University, Montpellier, France"},{"name":"Department of vascular Medicine, CHU N\u00eemes, Univ Montpellier, N\u00eemes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"04","key":"ref1","first-page":"508","article-title":"The catastrophic antiphospholipid syndrome","volume":"19","author":"R A Asherson","year":"1992","journal-title":"J Rheumatol"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients","volume":"77","author":"R A Asherson","year":"1998","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00005792-200111000-00002","article-title":"Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients","volume":"80","author":"R A Asherson","year":"2001","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.62.6.530","article-title":"Long term outcome of catastrophic antiphospholipid syndrome survivors","volume":"62","author":"D Erkan","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard.2005.037671","article-title":"The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients","volume":"65","author":"S Bucciarelli","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"S Bucciarelli","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry.\u201d","volume":"32","author":"R Cervera","year":"2009","journal-title":"J Autoimmun"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ket167","article-title":"Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases","volume":"52","author":"G Hanouna","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"09","key":"ref9","first-page":"481","article-title":"Catastrophic antiphospholipid syndrome: a case series","volume":"15","author":"S Shiber","year":"2013","journal-title":"Isr Med Assoc J"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"I Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"06","key":"ref11","first-page":"1033","article-title":"[Case series and clinical analysis of 14 cases of catastrophic antiphospholipid syndrome]","volume":"50","author":"J Y Gu","year":"2018","journal-title":"Beijing Da Xue Xue Bao"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jtha.2023.02.007","article-title":"Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients","volume":"21","author":"R Stammler","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"e32949","DOI":"10.1097\/MD.0000000000032949","article-title":"Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag: a case series and literature review","volume":"102","author":"W Garra","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"02","key":"ref14","first-page":"235","article-title":"Catastrophic antiphospholipid syndrome: a case series","volume":"33","author":"N Christopher","year":"2022","journal-title":"Indian J Radiol Imaging"},{"issue":"S 01","key":"ref15","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.medcli.2024.02.011","article-title":"Catastrophic antiphospholipid syndrome: lessons from the \u201cCAPS Registry.\u201d","volume":"163","author":"I Rodriguez-Pint\u00f3","year":"2024","journal-title":"Med Clin (Barc)"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00124743-200206000-00008","article-title":"Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment","volume":"8","author":"R A Asherson","year":"2002","journal-title":"J Clin Rheumatol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.autrev.2006.06.013","article-title":"Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome","volume":"6","author":"D Erkan","year":"2006","journal-title":"Autoimmun Rev"},{"issue":"03","key":"ref18","first-page":"160","article-title":"New approaches for managing antiphospholipid syndrome","volume":"5","author":"D Erkan","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome","volume":"13","author":"R Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.berh.2016.07.004","article-title":"Catastrophic antiphospholipid syndrome: the current management approach","volume":"30","author":"I Rodriguez-Pint\u00f3","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"R Cervera","year":"2018","journal-title":"J Autoimmun"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"I Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/09612033211070973","article-title":"Cost-effectiveness analysis of treatments for the first episode of catastrophic antiphospholipid syndrome: a study based on the catastrophic antiphospholipid syndrome registry","volume":"31","author":"G Quintana-L\u00f3pez","year":"2022","journal-title":"Lupus"},{"issue":"04","key":"ref24","first-page":"951","article-title":"[Intraalveolar hemorrhage as a cause of acute respiratory failure in catastrophic antiphospholipid syndrome]","volume":"106","author":"E Tuleja","year":"2001","journal-title":"Pol Arch Intern Med"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/0961203313491024","article-title":"Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations","volume":"22","author":"M L Rangel","year":"2013","journal-title":"Lupus"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-013-2454-5","article-title":"Recurrent episodes of hemorrhagic alveolitis in relapsing catastrophic antiphospholipid syndrome: the same side of the dark moon","volume":"33","author":"F Pieralli","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10067-004-1062-9","article-title":"Intracerebral hemorrhage in a patient with SLE and catastrophic antiphospholipid syndrome (CAPS): report of a case","volume":"24","author":"P Boura","year":"2005","journal-title":"Clin Rheumatol"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12028-017-0392-9","article-title":"Probable catastrophic antiphospholipid syndrome with intracerebral hemorrhage secondary to Epstein-Barr viral infection","volume":"28","author":"M P Plummer","year":"2018","journal-title":"Neurocrit Care"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00296-007-0348-z","article-title":"Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal haemorrhagic infarction","volume":"27","author":"I Starakis","year":"2007","journal-title":"Rheumatol Int"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjms.2022.08.010","article-title":"Bilateral adrenal hemorrhage: a rare presentation of catastrophic anti-phospholipid syndrome","volume":"365","author":"A A Oredegbe","year":"2023","journal-title":"Am J Med Sci"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/j.amjmed.2019.02.043","article-title":"Catastrophic antiphospholipid syndrome as a cause of severe gastrointestinal bleeding","volume":"132","author":"S K Jang","year":"2019","journal-title":"Am J Med"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/09273948.2020.1830122","article-title":"Catastrophic antiphospholipid syndrome: skin, eye and brain involvement","volume":"30","author":"J M Sanchez","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.surg.2010.07.007","article-title":"Catastrophic antiphospholipid syndrome (Asherson's syndrome) presenting with a splenic rupture","volume":"150","author":"K Okano","year":"2011","journal-title":"Surgery"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MBC.0000000000000210","article-title":"Catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia-related diseases or chance association?","volume":"26","author":"N T Tun","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"R A Asherson","year":"2003","journal-title":"Lupus"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ard.2004.025759","article-title":"Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome","volume":"64","author":"R Cervera","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"K Legault","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"K MJ Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease","volume":"2024","author":"B M Salter","year":"2024","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1513002","DOI":"10.3389\/ftox.2024.1513002","article-title":"Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a vessel-on-chip","volume":"6","author":"H J Weener","year":"2024","journal-title":"Front Toxicol"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1039\/D4LC00848K","article-title":"Blood-perfused vessels-on-chips stimulated with patient plasma recapitulate endothelial activation and microthrombosis in COVID-19","volume":"25","author":"H J Weener","year":"2025","journal-title":"Lab Chip"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.3390\/ijms24086908","article-title":"Microvascular environment influences brain microvascular heterogeneity: relative roles of astrocytes and oligodendrocytes for the EPCR expression in the brain endothelium","volume":"24","author":"M Thakar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.isci.2018.05.003","article-title":"Human organ-specific endothelial cell heterogeneity","volume":"4","author":"R Marcu","year":"2018","journal-title":"iScience"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"F Fischetti","year":"2005","journal-title":"Blood"},{"issue":"15","key":"ref45","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of \u03b22 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"C Agostinis","year":"2011","journal-title":"Blood"},{"issue":"6534","key":"ref46","doi-asserted-by":"crossref","first-page":"eabc0956","DOI":"10.1126\/science.abc0956","article-title":"Lipid presentation by the protein C receptor links coagulation with autoimmunity","volume":"371","author":"N M\u00fcller-Calleja","year":"2021","journal-title":"Science"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1016\/j.jtha.2025.08.027","article-title":"Simvastatin competitively inhibits cellular signaling of lipid-binding antiphospholipid antibodies","volume":"23","author":"D Marova","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1055\/s-0037-1613313","article-title":"NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies","volume":"88","author":"S Dunoyer-Geindre","year":"2002","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jth.12536","article-title":"NF-\u03baB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes","volume":"12","author":"K J Brandt","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"102628","DOI":"10.1016\/j.coi.2025.102628","article-title":"Complement in antiphospholipid syndrome, time to target?","volume":"96","author":"M A Dragon Durey","year":"2025","journal-title":"Curr Opin Immunol"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"S Chaturvedi","year":"2020","journal-title":"Blood"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ard.2025.07.016","article-title":"Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome","volume":"84","author":"N Ranjan","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"17301","DOI":"10.1038\/s41598-018-35034-x","article-title":"Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism","volume":"8","author":"A Stachowicz","year":"2018","journal-title":"Sci Rep"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"G Canaud","year":"2014","journal-title":"N Engl J Med"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/rth2.12090","article-title":"Effects of anti-\u03b22GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity","volume":"2","author":"C J Ng","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2021.04.021","article-title":"Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome","volume":"203","author":"V Bitsadze","year":"2021","journal-title":"Thromb Res"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome","volume":"29","author":"R Cervera","year":"2020","journal-title":"Lupus"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0961203306075562","article-title":"High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia","volume":"16","author":"I Martin-Toutain","year":"2007","journal-title":"Lupus"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1538-7836.2009.03335.x","article-title":"False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus","volume":"7","author":"R Pauzner","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic antiphospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"D Erkan","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"02","key":"ref61","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"U D Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry.\u201d","volume":"21","author":"B L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"21","key":"ref63","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"C M Yelnik","year":"2020","journal-title":"Blood"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"SI46","DOI":"10.1093\/rheumatology\/kead556","article-title":"What we know and what we don't know about catastrophic antiphospholipid syndrome","volume":"63","author":"I Rodriguez-Pint\u00f3","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/ard.2006.061671","article-title":"Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases","volume":"66","author":"J A G\u00f3mez-Puerta","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"05","key":"ref66","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/pn-2025-004512","article-title":"Catastrophic antiphospholipid antibody syndrome provoked by eltrombopag","volume":"25","author":"B C Sumanth T","year":"2025","journal-title":"Pract Neurol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.rpth.2023.100125","article-title":"Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag","volume":"7","author":"S Van de Vondel","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"09","key":"ref68","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3390\/jcm14093091","article-title":"Systemic lupus erythematosus with refractory immune thrombocytopenia progressing to catastrophic antiphospholipid syndrome during thrombopoietin receptor agonist therapy: a case report","volume":"14","author":"S W Chung","year":"2025","journal-title":"J Clin Med"},{"issue":"15","key":"ref69","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"M A Khamashta","year":"1995","journal-title":"N Engl J Med"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"R Goel","year":"2015","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2765-9663.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:09:46Z","timestamp":1769645386000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2765-9663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1055\/a-2765-9663","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}